UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status
Unique ID issued by UMIN UMIN000027260
Receipt No. R000031226
Scientific Title Analysis of Airway Inflammatory state alteration after intravenous L-Arginine loading
Date of disclosure of the study information 2017/05/07
Last modified on 2017/05/07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Analysis of Airway Inflammatory state alteration after intravenous L-Arginine loading
Acronym Alteration of Airway Inflammatory state after intravenous L-Arginine loading(AILA)
Scientific Title Analysis of Airway Inflammatory state alteration after intravenous L-Arginine loading
Scientific Title:Acronym Alteration of Airway Inflammatory state after intravenous L-Arginine loading(AILA)
Region
Japan

Condition
Condition Children who are required growth hormone (GH) stimulation tests to diagnose GH deficiency. These are children whose heights are two standard deviations (SD) below the mean for age and sex, and/or whose growth velocities are 1.5 SD below the mean for age and sex over 2 years' follow-up, or whose pediatric endocrinologists order growth hormone (GH) stimulation test for another reasons.
Classification by specialty
Clinical immunology Child
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The L-arginine loading test is widely used as a growth hormone provocative test. Intravenously injected L-arginine has been known to stimulate growth hormone secretion, but also serves as a substrate for nitric oxide production which potentially increases airway inflammatory markers, such as fraction exhaled nitric oxide (FeNO). Previous studies indicated that nebulized L-arginine and administrating L-arginine increase FeNO. Since pteridines works as co-enzyme for NO synthase (NOS), low levels of pteridines have been known to induce reactive oxygen species (ROS) instead of producing NO. Based on these facts, we hypothesize L-arginine loading will increase NO production with exhausting NOS co-enzyme, pteridines, and result in generating excessive reactive oxygen species (ROS) to aggravate airway inflammation.
Basic objectives2 Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes The alteration rate of oxidative stress level before L-arginine loading and 120 minutes after.
Key secondary outcomes In addition to the above mentioned items, the following items is investigated, including;
(1) The alteration rate of oxidative stress level, arginine level, pteridines level before L-arginine loading and 30,60,90,120 minutes after and next day in serum.
(2) Correlation between FeNO and oxidative stress level at each point.
(3) Correlation between FeNO and pteridines level at each point.
(4) Correlation between oxidative stress level and pteridines level at each point.

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Self control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Prevention
Type of intervention
Medicine
Interventions/Control_1 Dosing 500mg/kg L-arginine (maximal dose 30g) intravenous drip in 30minutes
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
2 years-old <=
Age-upper limit
15 years-old >=
Gender Male and Female
Key inclusion criteria Participants are scheduled to be examined by intravenous L-arginine loading test with short stature less than -2.0 standard deviation (SD) and/or low growth velocity <-1.5SD over 2 years of follow-up for age and sex, or another reasons their pediatric endocrinologist judge the L-arginine provocative test is necessary. They should be over 2 years old and under 16 years old , and give informed consent on the basis that the study is approved by each local ethics committee.
Key exclusion criteria Exclusion criteria are following items
1)Patients who are diagnosed with allergy of L-arginine
2) Patients who have used any steroid medications within one month
3) Either the investigator or the co-investigator judged as inappropriate patient for this clinical research
Target sample size 15

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Haruo Shintaku
Organization Osaka City University Graduate School of Medicine
Division name Department of Pediatrics
Zip code
Address 1-4-5,Asahi-machi,Abeno-ku,Osaka city,Osaka
TEL 06-6645-3816
Email m2017993@med.osaka-cu.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Saki Kasuga
Organization Osaka City University Graduate School of Medicine
Division name Department of Pediatrics
Zip code
Address 1-4-5,Asahi-machi,Abeno-ku,Osaka city,Osaka
TEL 06-6645-3816
Homepage URL
Email m2017993@med.osaka-cu.ac.jp

Sponsor
Institute Osaka City University Graduate School of Medicine
Institute
Department

Funding Source
Organization Osaka City University Graduate School of Medicine
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2017 Year 05 Month 07 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status
Date of protocol fixation
2017 Year 01 Month 11 Day
Date of IRB
Anticipated trial start date
2017 Year 02 Month 06 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 05 Month 07 Day
Last modified on
2017 Year 05 Month 07 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031226

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.